Locally ablative therapies for primary and metastatic liver cancer

Expert Review of Anticancer Therapy

Volumn 14, Issue 8, 2014, Pages 931-945

  Li, David ^a   Kang, Josephine ^b,c   Madoff, David C ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Flushing Radiation Oncology   (United States)

Author keywords

ablation; hepatocellular carcinoma; high intensity focused ultrasound; liver; metastasis; microwave; radiofrequency; radiosurgery; stereotactic body radiation therapy; thermal

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB; ALCOHOL;

ABLATION THERAPY; ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL EMBOLISM; BARCELONA CLINIC LIVER CANCER TREATMENT; BRACHYTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER OF THE LIVER ITALIAN PROGRAM; CANCER PROGNOSIS; CANCER STAGING; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COMPARATIVE EFFECTIVENESS; COMPLICATION; CRYOABLATION; CRYOSHOCK; CYTOTOXICITY; DISSEMINATED INTRAVASCULAR CLOTTING; DNA DAMAGE; DNA STRAND BREAKAGE; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HEALTH PROGRAM; HEART ARRHYTHMIA; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; INTERMETHOD COMPARISON; IRREVERSIBLE ELECTROPORATION; LIVER CANCER; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER METASTASIS; LIVER SURGERY; LIVER TOXICITY; MICROWAVE THERAPY; MORBIDITY; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERCUTANEOUS ETHANOL INJECTION; PERCUTANEOUS LASER ABLATION; PLEURA EFFUSION; PRACTICE GUIDELINE; RADIATION DOSE; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; REVIEW; SAFETY; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC TREATMENT; SURVIVAL RATE; THERMAL INJURY; THORACOCENTESIS; THROMBOCYTOPENIA; ANIMAL; CATHETER ABLATION; CRYOSURGERY; ELECTROCHEMOTHERAPY; LIVER NEOPLASMS; LOW LEVEL LASER THERAPY; PATHOLOGY; PROCEDURES; RADIOSURGERY; SECONDARY;

ABLATION TECHNIQUES; ANIMALS; CATHETER ABLATION; CRYOSURGERY; ELECTROCHEMOTHERAPY; ETHANOL; HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION; HUMANS; LASER THERAPY; LIVER NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RADIOSURGERY;

EID: 84905060638     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.911091     Document Type: Review

References (122)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61(2):69-90
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27(9):1485-91
3. Nathan H, Segev DL, Mayo SC, et al. National trends in surgical procedures for hepatocellular carcinoma: 1998-2008. Cancer 2012;118(7):1838-44
4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108
5. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012. [Epub ahead to print]
6. Geoghegan JG, Scheele J. Treatment of colorectal liver metastases. Br J Surg 1999; 86(2):158-69
7. Mahnken AH, Pereira PL, de Baere T. Interventional oncologic approaches to liver metastases. Radiology 2013;266(2):407-30
8. Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: A critical view of the evidence. Nat Rev Gastroenterol Hepatol 2013;10(1): 34-42
9. Benson AB 3rd, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: Hepatobiliary cancers. J Natl Compr Canc Netw 2009;7(4): 350-91
10. Benson AB 3rd, Bekaii-Saab T, Chan E, et al. Metastatic colon cancer, version 3.2013: Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2013;11(2):141-52.quiz 152
11. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int 2012; 32(Suppl 1):2-8
12. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28(3):751-5
13. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999;19(3): 329-38
14. Hsu CY, Hsia CY, Huang YH, et al. Selecting an optimal staging system for hepatocellular carcinoma: Comparison of 5 currently used prognostic models. Cancer 2010;116(12):3006-14
15. Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives. Hepatology 2013;58(6):2188-97
16. Salem R, Lewandowski RJ. Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol 2013;11(6):604-11. quiz e643-604
17. Memon K, Lewandowski RJ, Riaz A, Salem R. Chemoembolization and radioembolization for metastatic disease to the liver: Available data and future studies. Curr Treat Options Oncol 2012;13(3): 403-15
18. Ricke J, Mohnike K, Pech M, et al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2010;78(2):479-85
19. Mohnike K, Wieners G, Pech M, et al. Image-guided interstitial high-dose-rate brachytherapy in hepatocellular carcinoma. Dig Dis 2009;27(2):170-4
20. Wieners G, Pech M, Hildebrandt B, et al. Phase II feasibility study on the combination of two different regional treatment approaches in patients with colorectal "liver-only" metastases: Hepatic interstitial brachytherapy plus regional chemotherapy. Cardiovasc Intervent Radiol 2009;32(5):937-45
21. Brouquet A, Abdalla EK, Kopetz S, et al. High survival rate after two-stage resection of advanced colorectal liver metastases: Response-based selection and complete resection define outcome. J Clin Oncol 2011;29(8):1083-90
22. Johnston FM, Mavros MN, Herman JM, Pawlik TM. Local therapies for hepatic metastases. J Natl Compr Canc Netw 2013; 11(2):153-60
23. Pawlik TM, Olino K, Gleisner AL, et al. Preoperative chemotherapy for colorectal liver metastases: Impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007;11(7):860-8
24. Tanabe G, Sakamoto M, Akazawa K, et al. Intraoperative risk factors associated with hepatic resection. Br J Surg 1995;82(9): 1262-5
25. Tsao JI, Loftus JP, Nagorney DM, et al. Trends in morbidity and mortality of hepatic resection for malignancy. A matched comparative analysis. Ann Surg 1994; 220(2):199-205
26. Madoff DC, Hicks ME, Vauthey JN, et al. Transhepatic portal vein embolization: Anatomy, indications, and technical considerations. Radiographics 2002;22(5): 1063-76
27. Cunningham SC, Tsai S, Marques HP, et al. Management of early hepatocellular carcinoma in patients with wellcompensated cirrhosis. Ann Surg Oncol 2009;16(7):1820-31
28. DuBay DA, Sandroussi C, Kachura JR, et al. Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB 2011;13(1): 24-32
29. Heckman JT, Devera MB, Marsh JW, et al. Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol 2008; 15(11):3169-77
30. Katz AW, Chawla S, Qu Z, et al. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: Clinical outcome and pathologic correlation. Int J Radiat Oncol Biol Phys 2012;83(3):895-900
31. Zanus G, Boetto R, Gringeri E, et al. Microwave thermal ablation for hepatocarcinoma: Six liver transplantation cases. Transplant Proc 2011;43(4): 1091-4
32. Jaeck D, Oussoultzoglou E, Rosso E, et al. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 2004;240(6): 1037-49.discussion 1049-51
33. Knavel EM, Brace CL. Tumor ablation: Common modalities and general practices. Tech Vasc Interv Radiol 2013;16(4): 192-200
34. Goodhead DT. The initial physical damage produced by ionizing radiations. Int J Radiat Biol 1989;56(5):623-34
35. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009;461(7267):1071-8
36. Ahmed M, Brace CL, Lee FT Jr, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology 2011; 258(2):351-69
37. Haemmerich D, Pilcher TA. Convective cooling affects cardiac catheter cryoablation and radiofrequency ablation in opposite directions. Conf Proc IEEE Eng Med Biol Soc 2007;1499-502
38. Dupuy DE, Goldberg SN. Image-guided radiofrequency tumor ablation: Challenges and opportunities-part II. J Vasc Interv Radiol 2001;12(10):1135-48
39. Goldberg SN. Radiofrequency tumor ablation: Principles and techniques. Eur J Ultrasound 2001;13(2):129-47
40. Rhim H, Dodd GD 3rd, Chintapalli KN, et al. Radiofrequency thermal ablation of abdominal tumors: Lessons learned from complications. Radiographics 2004;24(1): 41-52
41. Huffman SD, Huffman NP, Lewandowski RJ, Brown DB. Radiofrequency ablation complicated by skin burn. Semin Intervent Radiol 2011; 28(2):179-82
42. Lu DS, Raman SS, Limanond P, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol 2003;14(10): 1267-74
43. Weis S, Franke A, Mossner J, et al. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev 2013;12:CD003046
44. Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010;252(6):903-12
45. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243(3):321-8
46. Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012;57(4):794-802
47. Brunello F, Veltri A, Carucci P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol 2008;43(6):727-35
48. Giorgio A, Di Sarno A, De Stefano G, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: An Italian randomized controlled trial. Anticancer Res 2011;31(6): 2291-5
49. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228(1): 235-40
50. Lin SM, Lin CJ, Lin CC, et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma > or =4 cm Gastroenterology 2004 127 6 1714-23
51. Lin SM, Lin CJ, Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005;54(8):1151-6
52. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129(1):122-30
53. Shibata T, Iimuro Y, Yamamoto Y, et al. Small hepatocellular carcinoma: Comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 2002;223(2):331-7
54. Ferrari FS, Megliola A, Scorzelli A, et al. Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long-term results. Radiol Med (Torino) 2007;112(3): 377-93
55. White RR, Avital I, Sofocleous CT, et al. Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. J Gastrointest Surg 2007; 11(3):256-63
56. Leblanc F, Fonck M, Brunet R, et al. Comparison of hepatic recurrences after resection or intraoperative radiofrequency ablation indicated by size and topographical characteristics of the metastases. Eur J Surg Oncol 2008;34(2):185-90
57. Berber E, Tsinberg M, Tellioglu G, et al. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg 2008;12(11): 1967-72
58. Lee WS, Yun SH, Chun HK, et al. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. J Clin Gastroenterol 2008;42(8):945-9
59. Reuter NP, Woodall CE, Scoggins CR, et al. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: Therapeutically equivalent? J Gastrointest Surg 2009;13(3):486-91
60. Hur H, Ko YT, Min BS, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 2009;197(6):728-36
61. McKay A, Fradette K, Lipschitz J. Long-term outcomes following hepatic resection and radiofrequency ablation of colorectal liver metastases. HPB Surg 2009;2009:346863
62. Otto G, Duber C, Hoppe-Lotichius M, et al. Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery. Ann Surg 2010;251(5):796-803
63. Schiffman SC, Bower M, Brown RE, et al. Hepatectomy is superior to thermal ablation for patients with a solitary colorectal liver metastasis. J Gastrointest Surg 2010;14(12): 1881-6.discussion 1886-7
64. Lee H, Jin GY, Han YM, et al. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy. Cardiovasc Intervent Radiol 2012;35(2):343-50
65. Gleisner AL, Choti MA, Assumpcao L, et al. Colorectal liver metastases: Recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg 2008;143(12):1204-12
66. Kim KH, Yoon YS, Yu CS, et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. J Korean Surg Soc 2011; 81(1):25-34
67. Schramm W, Yang D, Wood BJ, et al. Contribution of direct heating, thermal conduction and perfusion during radiofrequency and microwave ablation. Open Biomed Eng J 2007;1:47-52
68. Ding J, Jing X, Liu J, et al. Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma. Eur J Radiol 2013;82(9):1379-84
69. Ding J, Jing X, Liu J, et al. Complications of thermal ablation of hepatic tumours: Comparison of radiofrequency and microwave ablative techniques. Clin Radiol 2013;68(6):608-15
70. Zhang L, Wang N, Shen Q, et al. Therapeutic Efficacy of Percutaneous Radiofrequency Ablation versus Microwave Ablation for Hepatocellular Carcinoma. PLoS ONE 2013;8(10):e76119
71. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009;27(10): 1572-8
72. Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013;31(13):1631-9
73. Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010;76(Suppl 3):S10-19
74. Dawson LA, Eccles C, Bissonnette JP, Brock KK. Accuracy of daily image guidance for hypofractionated liver radiotherapy with active breathing control. Int J Radiat Oncol Biol Phys 2005;62(4): 1247-52
75. Wunderink W, Mendez Romero A, de Kruijf W, et al. Reduction of respiratory liver tumor motion by abdominal compression in stereotactic body frame, analyzed by tracking fiducial markers implanted in liver. Int J Radiat Oncol Biol Phys 2008;71(3):907-15
76. Wagman R, Yorke E, Ford E, et al. Respiratory gating for liver tumors: Use in dose escalation. Int J Radiat Oncol Biol Phys 2003;55(3):659-68
77. Dawson LA. RTOG 1112: Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy followed by Sorafenib in Hepatocellular Carcinoma.
78. Blomgren H, Lax I, Naslund I, Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995;34(6):861-70
79. Mendez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol 2006;45(7):831-7
80. Cardenes HR, Price TR, Perkins SM, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010;12(3): 218-25
81. Kwon JH, Bae SH, Kim JY, et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 2010;10:475
82. Seo YS, Kim MS, Yoo SY, et al. Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 2010;102(3):209-14
83. Louis C, Dewas S, Mirabel X, et al. Stereotactic radiotherapy of hepatocellular carcinoma: Preliminary results. Technol Cancer Res Treat 2010;9(5):479-87
84. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26(4):657-64
85. Rule W, Timmerman R, Tong L, et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol 2011;18(4): 1081-7
86. Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009;27(10):1585-91
87. Goodman KA, Wiegner EA, Maturen KE, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 2010;78(2):486-93
88. Mearini L. High intensity focused ultrasound, liver disease and bridging therapy. World J Gastroenterol 2013; 19(43):7494-9
89. Cheung TT, Fan ST, Chan SC, et al. High-intensity focused ultrasound ablation: An effective bridging therapy for hepatocellular carcinoma patients. World J Gastroenterol 2013;19(20):3083-9
90. Shen HP, Gong JP, Zuo GQ. Role of high-intensity focused ultrasound in treatment of hepatocellular carcinoma. Am Surg 2011;77(11):1496-501
91. Xu G, Luo G, He L, et al. Follow-up of high-intensity focused ultrasound treatment for patients with hepatocellular carcinoma. Ultrasound Med Biol 2011;37(12):1993-9
92. Ng KK, Poon RT, Chan SC, et al. High-intensity focused ultrasound for hepatocellular carcinoma: A single-center experience. Ann Surg 2011;253(5):981-7
93. Wu F, Wang ZB, Chen WZ, et al. Extracorporeal high intensity focused ultrasound ablation in the treatment of patients with large hepatocellular carcinoma. Ann Surg Oncol 2004;11(12):1061-9
94. Wu F, Wang ZB, Chen WZ, et al. Extracorporeal high intensity focused ultrasound ablation in the treatment of 1038 patients with solid carcinomas in China: An overview. Ultrason Sonochem 2004;11(3-4):149-54
95. Wu F, Wang ZB, Chen WZ, et al. Advanced hepatocellular carcinoma: Treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization. Radiology 2005;235(2):659-67
96. Lu DS, Kee ST, Lee EW. Irreversible electroporation: Ready for prime time? Tech Vasc Interv Radiol 2013;16(4):277-86
97. Ben-David E, Appelbaum L, Sosna J, et al. Characterization of irreversible electroporation ablation in in vivo porcine liver. AJR Am J Roentgenol 2012;198(1): W62-8
98. Silk MT, Wimmer T, Lee KS, et al. Percutaneous Ablation of Peribiliary Tumors with Irreversible Electroporation. J Vasc Interv Radiol 2013;25(1):112-18
99. Deodhar A, Dickfeld T, Single GW, et al. Irreversible electroporation near the heart: Ventricular arrhythmias can be prevented with ECG synchronization. AJR Am J Roentgenol 2011;3):W330-5
100. Cannon R, Ellis S, Hayes D, et al. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol 2013;107(5):544-9
101. Cheung W, Kavnoudias H, Roberts S, et al. Irreversible electroporation for unresectable hepatocellular carcinoma: Initial experience and review of safety and outcomes. Technol Cancer Res Treat 2013;12(3):233-41
102. Kingham TP, Karkar AM, D'Angelica MI, et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg 2012; 215(3):379-87
103. Thomson KR, Cheung W, Ellis SJ, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 2011;22(5):611-21
104. McCarley JR, Soulen MC. Percutaneous ablation of hepatic tumors. Semin Intervent Radiol 2010;27(3):255-60
105. Ebara M, Okabe S, Kita K, et al. Percutaneous ethanol injection for small hepatocellular carcinoma: Therapeutic efficacy based on 20-year observation. J Hepatol 2005;43(3):458-64
106. Taniguchi M, Kim SR, Imoto S, et al. Long-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinoma. World J Gastroenterol 2008;14(13):1997-2002
107. Smith MT, Ray CE. The treatment of primary and metastatic hepatic neoplasms using percutaneous cryotherapy. Semin Intervent Radiol 2006;23(1):39-46
108. Huang YZ, Zhou SC, Zhou H, Tong M. Radiofrequency ablation versus cryosurgery ablation for hepatocellular carcinoma: A meta-analysis. Hepatogastroenterology 2013;60(125):1131-5
109. Pacella CM, Francica G, Di Costanzo GG. Laser ablation for small hepatocellular carcinoma. Radiol Res Pract 2011;2011:595627
110. Vogl TJ, Straub R, Eichler K, et al. Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: Experience with complications in 899 patients (2,520 lesions). Radiology 2002;225(2): 367-77
111. Pacella CM, Francica G, Di Lascio FM, et al. Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: A retrospective analysis. J Clin Oncol 2009;27(16):2615-21
112. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010; 52(2):762-73
113. Lu Z, Wen F, Guo Q, et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: A meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2013; 25(2):187-94
114. Ni JY, Liu SS, Xu LF, et al. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2013;19(24):3872-82
115. Jiang G, Xu X, Ren S, Wang L. Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma. Tumour Biol 2013. [Epub ahead to print]
116. Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: A prospective randomized trial. J Clin Oncol 2013;31(4):426-32
117. Hurwitz MD, Hansen JL, Prokopios-Davos S, et al. Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer: Long-term results from Dana-Farber Cancer Institute study 94-153. Cancer 2011;117(3): 510-16
118. Zagar TM, Oleson JR, Vujaskovic Z, et al. Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: A review of the randomised data. Int J Hyperthermia 2010; 26(7):612-17
119. Goldberg SN. Science to practice: Can we expand focal interventional oncologic ablation treatments into an effective systemic therapy? Radiology 2013;267(2): 321-3
120. Soundararajan A, Dodd GD 3rd, Bao A, et al. Chemoradionuclide therapy with 186Re-labeled liposomal doxorubicin in combination with radiofrequency ablation for effective treatment of head and neck cancer in a nude rat tumor xenograft model. Radiology 2011;261(3):813-23
121. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379(9822):1245-55
122. Scorsetti M, Arcangeli S, Tozzi A, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 2013;86(2):336-342